1 Integrative approach to interpret DYRK1A variants, leading to a frequent 2 neurodevelopmental disorder

3 Jeremie Courraud^{1,2,3,4}, Eric Chater-Diehl⁵, Benjamin Durand^{1,2,3,4}, Marie Vincent⁶, Maria del
4 Mar Muniz Moreno^{1,2,3,4}, Imène Boujelbene^{1,2,3,4}, Nathalie Drouot^{1,2,3,4}, Loréline
5 Genschik^{1,2,3,4}, Elise Schaefer⁷, Mathilde Nizon⁶, Bénédicte Gerard⁸, Marc Abramowicz⁹,
6 Benjamin Cogné⁶, Lucas Bronicki¹⁰, Lydie Burglen¹¹, Magalie Barth¹², Perrine Charles¹³,
7 Estelle Colin¹², Christine Coubes¹⁴, Albert David⁶, Bruno Delobel¹⁵, Florence Demurger¹⁶,
8 Sandrine Passemard¹⁷, Anne-Sophie Denommé¹⁸, Laurence Faivre¹⁸, Claire Feger⁸, Mélanie
9 Fradin²⁰, Christine Francannet²¹, David Genevieve¹⁴, Alice Goldenberg²², Anne-Marie
10 Guerrot²², Bertrand Isidor⁶, Katrine M. Johannesen^{24,25}, Boris Keren¹³, Maria Kibæk²³, Paul
11 Kuentz¹⁸, Michele Mathieu-Dramard²⁶, Bénédicte Demeer²⁶, Julia Metreau²⁷, Rikke
12 Steensbjerre Møller^{24,25}, Sébastien Moutton¹⁸, Laurent Pasquier²⁰, Kristina Pilekær
13 Sørensen²³, Laurence Perrin²⁸, Mathilde Renaud²⁹, Pascale Saugier²², Joane Svane²³, Julien
14 Thevenon³⁰, Frederic Tran Mau Them¹⁸, Cathrine Elisabeth Tronhjem²³, Antonio Vitobello¹⁸,
15 Valerie Layet³¹, Marie-Christine Birling³², Severine Drunat³³, Allan Bayat²³, Christèle
16 Dubourg³⁴, Salima El Chehadeh⁷, Christina Fagerberg²³, Cyril Mignot¹², Michel Guipponi⁹,
17 Thierry Bienvenu³⁵, Yann Herault^{1,2,3,4}, Julie Thompson³⁶, Marjolaine Willems¹⁴, Jean-Louis
18 Mandel^{1,2,3,4}, Rosanna Weksberg⁵, *Amélie Piton^{1,2,3,4,8,37}

19 AFFILIATIONS

20 ¹ Institut de Génétique et de Biologie Moléculaire et Cellulaire, Illkirch 67400, France
21 ² Centre National de la Recherche Scientifique, UMR7104, Illkirch 67400, France
22 ³ Institut National de la Santé et de la Recherche Médicale, U964, Illkirch 67400, France
23 ⁴ Université de Strasbourg, Illkirch 67400, France
24 ⁵ Genetics and Genome Biology, The Hospital for Sick Children, Toronto, ON M5G 1X8,
25 Canada
26 ⁶ Service de Génétique Médicale, CHU de Nantes & Inserm, CNRS, Université de Nantes,
27 l'institut du thorax, 44000 Nantes, France
28 ⁷ Service de Génétique Médicale, IGMA, Hôpitaux Universitaires de Strasbourg, Strasbourg,
29 France
30 ⁸ Unité de Génétique Moléculaire, IGMA, Hôpitaux Universitaire de Strasbourg, Strasbourg,
31 France
32 ⁹ Service of Genetic Medicine, University Hospitals of Geneva, Geneva, Switzerland

- 33 ¹⁰ Department of Genetics, CHEO, Ottawa, ON, Canada.
- 34 ¹¹ Centre de référence des malformations et maladies congénitales du cervelet et Département
35 de génétique et embryologie médicale, APHP, Sorbonne Université, Hôpital Armand
36 Trousseau, 75012 Paris, France
- 37 ¹² Pediatrics & Biochemistry and Genetics, Department, Angers Hospital, Angers, France.
- 38 ¹³ Genetic Department, University Hospital Pitié-Salpêtrière, AP-HP, Paris, France
- 39 ¹⁴ Département de Génétique Médicale maladies rares et médecine personnalisée, Centre de
40 Référence Maladies Rares Anomalies du Développement, Hôpital Arnaud de Villeneuve,
41 Université Montpellier, France
- 42 ¹⁵ Centre de Génétique Chromosomique, GHICL, Hôpital Saint Vincent de Paul, Lille, France
- 43 ¹⁶ Service de Génétique, CH Bretagne Atlantique- Vannes
- 44 ¹⁷ Département de Génétique, Hôpital Universitaire Robert Debré, APHP, Paris, France.
- 45 ¹⁸ Centre de Génétique et Centre de Référence Anomalies du développement et Syndromes
46 malformatifs, Hôpital d'Enfants and INSERM UMR1231 GAD, FHU TRANSLAD, CHU de
47 Dijon, Dijon, France
- 48 ¹⁹ Unité Fonctionnelle d'Innovation en Diagnostique Génomique des Maladies Rares, Pôle de
49 Biologie, FHU-TRANSLAD, CHU Dijon Bourgogne, F-21000, Dijon, France
- 50 ²⁰ Centre de Référence Maladies Rares, Unité Fonctionnelle de Génétique Médicale, CHU,
51 Rennes, France
- 52 ²¹ Service de Génétique médicale, CHU de Clermont-Ferrand, Clermont-Ferrand, France
- 53 ²² Normandie Univ, UNIROUEN, Inserm U1245 and Rouen University Hospital, Department
54 of Genetics and Reference Center for Developmental Disorders , F 76000, Normandy Center
55 for Genomic and Personalized Medicine, Rouen, France
- 56 ²³ Department of Clinical Genetics, Odense Denmark Hospital, Odense University Hospital,
57 Odense, Denmark
- 58 ²⁴ Department of Epilepsy Genetics and Personalized Treatment, The Danish Epilepsy Centre,
59 Dianalund, Denmark
- 60 ²⁵ Institute for Regional Health Services, University of Southern Denmark, Odense Denmark
- 61 ²⁶ Service de Génétique Clinique, Centre de référence maladies rares, CHU d'Amiens-site Sud,
62 Amiens, France
- 63 ²⁷ APHP, Service de neurologie pédiatrique, Hôpital Universitaire Bicetre, Le Kremlin-
64 Bicetre, France
- 65 ²⁸ Department of Genetics, Robert Debré Hospital, AP-HP, Paris, France
- 66 ²⁹ Service de Génétique Clinique et de Neurologie, Hôpital Brabois Enfants, Nancy, France

³⁰ Department of Genetics and Reproduction, Centre Hospitalo-Universitaire Grenoble-Alpes, Grenoble, France

³¹ Consultations de génétique, Groupe Hospitalier du Havre, Le Havre, France

³² ICS, Mouse Clinical Institute, Illkirch-Graffenstaden, France

³³ Département de Génétique, Hôpital Universitaire Robert Debré, Paris

³⁴ Laboratoire de Génétique Moléculaire, CHU Pontchaillou, UMR 6290 CNRS, IGDR, Faculté de Médecine, Université de Rennes 1, Rennes, France

³⁵ Molecular Genetics Laboratory, Cochin Hospital, APHP.Centre-Université de Paris, and INSERM UMR 1266, Institut de Psychiatrie et de Neurosciences de Paris, 75014 Paris, France

³⁶ Complex Systems and Translational Bioinformatics (CSTB), ICube laboratory - CNRS, Fédération de Médecine Translationnelle de Strasbourg (FMTS), University of Strasbourg, Strasbourg, France

³⁷ Institut Universitaire de France

81

82

The authors declare no conflict of interest.

84

*Address for correspondence and material request:

Amélie Piton, PhD

Laboratoire "Mécanismes génétiques des maladies neurodéveloppementales", IGBMC, Illkirch, France

Tel : +33369551652

E-mail: piton@igbmc.fr

91

Competing interests

None.

94

95

96

97

98 **AbBSTRACT**

99 *DYRK1A*-related intellectual disability (ID) is among the most frequent monogenic form of
100 ID. We refined the description of this disorder by reporting clinical and molecular data of
101 forty individuals with ID harboring *DYRK1A* variants. We developed a combination of tools
102 to interpret missense variants, which remains a major challenge in human genetics: i) a
103 specific *DYRK1A* clinical score, ii) amino acid conservation data generated from one hundred
104 of *DYRK1A* sequences across different taxa, iii) *in vitro* overexpression assays to study level,
105 cellular localization, and kinase activity of *DYRK1A* mutant proteins, and iv) a specific blood
106 DNA methylation signature. This integrative approach was successful to reclassify several
107 variants as pathogenic. However, we questioned the involvement of some others, such as
108 p.Thr588Asn, yet reported as pathogenic, and showed it does not cause obvious phenotype in
109 mice, emphasizing the need to take care when interpreting variants, even those occurring *de*
110 *novo*.

111
112 **Keywords:** *DYRK1A*, clinical score, missense variants, variant of unknown significance
113 (VUS), functional assays; episignature

114

115

116

117

118

119

120

121

122

123

124

125

INTRODUCTION

Intellectual disability (ID) and autism spectrum disorder (ASD) are two highly heterogeneous groups of neurodevelopmental disorders (NDD) with substantial genetic contributions which overlap strongly both at the clinical and genetic levels. Single genetic events account for about 50% of ID cases (Vissers *et al*, 2016) and for a much smaller proportion of cases with ASD without ID. More than one thousand genes have been implicated in monogenic forms of NDD, with an important contribution of autosomal dominant forms caused by *de novo* mutations (Deciphering Developmental Disorders Study, 2017). One of these genes, *DYRK1A* (*dual specificity tyrosine phosphorylation regulated kinase 1A*)(Gonzalez-Mantilla *et al*, 2016), located on chromosome 21, is among the genes the most frequently mutated in individuals with ID (Deciphering Developmental Disorders Study, 2017).

The first *DYRK1A* disruptions were identified in individuals with intrauterine growth restriction (IUGR), primary microcephaly and epilepsy (Møller *et al*, 2008). Few years after, the first frameshift variant was described in a patient with similar features (Courcet *et al*, 2012). The clinical spectrum associated with *DYRK1A* pathogenic variants (*MRD7 for Mental Retardation 7* in OMIM) was further refined with the publication of additional patients, presenting suggestive facial dysmorphism, severe speech impairment and feeding difficulty, while epilepsy and prenatal microcephaly were not always present (Bronicki *et al*, 2015; Blackburn *et al*, 2019a; van Bon *et al*, 2011, 2016; O’Roak *et al*, 2012; Courcet *et al*, 2012; Okamoto *et al*, 2015; Iglesias *et al*, 2014; Ruaud *et al*, 2015; Ji *et al*, 2015; Rump *et al*, 2016; Luco *et al*, 2016; Murray *et al*, 2017; Evers *et al*, 2017; Lee *et al*, 2020a; Dang *et al*, 2018; Qiao *et al*, 2019; Ernst *et al*, 2020; Tran *et al*, 2020; Møller *et al*, 2008; Fujita *et al*, 2010; Oegema *et al*, 2010; Yamamoto *et al*, 2011; Valetto *et al*, 2012; Kim *et al*, 2017; Meissner *et al*, 2020; Matsumoto *et al*, 1997). Pathogenic variants were also identified in cohorts of individuals with ASD (O’Roak *et al*, 2012), but all have ID (Earl *et al*, 2017). The *DYRK1A* gene encodes a dual tyrosine-serine/threonine (Tyr-Ser/Thr) kinase 763 (NM_001396.4) amino acids in length (Becker, 2011) including a DH (DYRK Homology-box) domain (aa 137-154), two nuclear localization signal sequence (NLS)(NLS1 aa 92-104, NLS2 aa 389-395), a central catalytic domain (aa 159-479, including Tyrosine 321, involved in the activation of DYRK1A by autophosphorylation (Himpel *et al*, 2001), some Ser/Thr repeats, a poly-histidine sequence (localization to nuclear speckles) and a PEST domain (aa 525-619)

(regulation of DYRK1A level by degradation). *DYRK1A* is ubiquitously expressed during embryonic development and in adult tissues. Its location is both cytoplasmic and nuclear and varies by cell type and stage of development (Hämmerle *et al*, 2008). By the number and diversity of its proposed protein targets, DYRK1A regulates numerous cellular functions (reviews (Tejedor & Hämmerle, 2011; Duchon & Herault, 2016)), among them the among them the MAPT (Tau) protein phosphorylated by DYRK1A on its Thr212 position (Woods *et al*, 2001).

High Throughput Sequencing (HTS) has revolutionized the identification of genetic variants for diagnostic applications but a major challenge remains in the interpretation of the vast number of variants, especially for highly heterogeneous disease such ID. A combination of genetic, clinical and functional approaches, summarized by the American College of Medical Genetics (ACMG), are commonly used to interpret these variants (Richards *et al*, 2015). A significant proportion of the variants, especially the missense variants, remain classified as variants of unknown significance (VUS, according to ACMG) after the primary analysis. For autosomal dominant forms of ID with complete penetrance such as *DYRK1A*-related ID, the *de novo* occurrence of a variant is a strong argument for pathogenicity, however: 1) the genotype of the parents is not always available, 2) there is a probability, low but not negligible, that a variant will occur *de novo* in this gene with no link with the disease. The clinical argument might also lead to misinterpretation: under-interpretation when the clinical signs do not correspond to the initial phenotype described, over-interpretation if too much weight is given to unspecific signs. Many tools have been developed over the past ten years to predict *in silico* the pathogenicity of missense variants but they remain imperfect and *in vitro* (or *in vivo*) functional tests are useful to evaluate the true consequences of a variant, especially in the research setting as these are labor intensive and require the development of gene/protein-specific assays. DNA methylation (DNAm) is also a powerful tool to test variant pathogenicity in disorders associated with epigenetic regulatory genes. We discovered that pathogenic variants in these genes can exhibit disorder-specific DNAm signatures comprised of consistent, multilocus DNAm alterations in peripheral blood (Choufani *et al*, 2015). More than 50 DNAm signatures associated with disorders of the epigenetic machinery have now been established (Choufani *et al*, 2015, 2020; Butcher *et al*, 2017; Aref-Eshghi *et al*, 2019; Chater-Diehl *et al*, 2019). DNAm signatures are highly sensitive and specific for each condition, able to discriminate between related disorders, and useful for classifying variants in

these genes as pathogenic or benign (Choufani *et al*, 2015; Butcher *et al*, 2017; Aref-Eshghi *et al*, 2019; Chater-Diehl *et al*, 2019). *DYRK1A* has numerous targets, and while it is not well described as an epigenetic regulator, it has been shown to phosphorylate Histone H3 (Jang *et al*, 2014) as well proteins with acetyltransferase activity such as CBP and p300 (Li *et al*, 2018). Therefore, we hypothesized that pathogenic variants in *DYRK1A* would be associated with a specific DNAm signature in blood.

We reviewed the clinical signs in 32 individuals carrying deletions or clearly pathogenic variants in *DYRK1A* to refine the clinical spectrum of *DYRK1A*-related ID and we developed a clinical score, CS_{DYRK1A}, to help to recognize affected individuals and to interpret *DYRK1A* variants (reverse phenotyping). In parallel, we developed *in silico* and *in vitro* approaches to assess variant effects on *DYRK1A* function. Finally, we defined a DNAm signature specific to *DYRK1A*-related ID in patient blood. We used this combination of clinical, *in silico*, *in vitro* and DNAm tools to interpret seventeen variants identified in *DYRK1A* in patients with ID/NDD and demonstrated the utility of this multifaceted approach in avoiding misinterpretation/optimizing accurate interpretation of *DYRK1A* variants.

METHODS

Patients and molecular analysis

Variants in *DYRK1A* were identified during genetic analyses carried out in individuals referred to clinical genetic services for intellectual disability in France, Denmark and Switzerland: CGH-array, direct Sanger sequencing of *DYRK1A* coding sequences, targeted next generation sequencing of genes involved in ID (TES)(Redin *et al*, 2014; Carion *et al*, 2020; Nasser *et al*, 2020), trio or simplex clinical or exome sequencing (CES, ES). The variants reported here were confirmed by an additional method. They are reported according to standardized nomenclature defined by the reference human genome GRCh37/hg19 and the *DYRK1A* isoform NM_001396.4. Predictions of missense variant effects were performed using *in silico* tools such Combined Annotation Dependent Depletion (CADD)(Kircher *et al*, 2014). Predictions of variant effect on splicing were performed using NnsplICE (Reese *et al*, 1997) and MaxEnt (Eng *et al*, 2004). Fibroblasts established from skin biopsies were available for Ind #1, #11, #22 and #24 and were cultivated as previously described (Balak *et*

al, 2019). Paxgene blood samples were collected for Ind #9, #18, #19 and #30. mRNA extraction, RT-PCR or qPCR were performed as previously described using specific primers (sequences available on request). For RNA sequencing, libraries, sequencing and analysis were performed as previously described (Quartier *et al*, 2018).

Phenotypic analysis and clinical scoring

A clinical summary, a checklist, and photographs when possible, were provided by the referring clinicians for the 42 individuals reported here as well as for six French individuals previously published (individuals Bronicki #2, #3, #8, #9 and #10 and individual Ruaud #2)(Bronicki *et al*, 2015; Ruaud *et al*, 2015). Based on the most frequent signs and the morphometric characteristics presented by 32 individuals with truncating variants in *DYRK1A* (nonsense, frameshift, splice, deletions or translocations affecting *DYRK1A*), a clinical score out of 20 was established (DYRK1A_I, n=21 individuals with photographs available **Table S1**). This clinical score was calculated in a second cohort (replication cohort, DYRK1A_R, n=13) which includes individuals already described in previous publications carrying a truncating variant (Bronicki *et al*, 2015; Ruaud *et al*, 2015; van Bon *et al*, 2016). We tested the score on individuals affected by other frequent monogenic forms of ID, caused by pathogenic variants in *DDX3X* (n=5), *ANKRD11* (n=5), *ARID1B* (n=8), *KMT2A* (n=6), *MED13L* (n=5), *SHANK3* (n=6) or *TCF4* (n=6, from (Mary *et al*, 2018)) gene. Score based on facial features was established from photographs by experimented clinical geneticists.

Definition of sets of missense variants and conservation analysis

To evaluate which tools are pertinent to predict effect of missense variants on the DYRK1A protein, we used different sets of variants : 1) a set of variants presumed to be benign, i.e missense variants annotated as “benign”/“likely benign” in ClinVar as well as variants reported more than once in GnomAD (november 2019 release) (negative N-set, n=115), 2) a set of missense variants reported as “pathogenic”/“likely pathogenic” in Clinvar (positive P-set, n=16), and 3) all the missense variants reported here, in literature, or as VUS in Clinvar (test T-set, n=44)(**Table S2**). Orthologs of human DYRK1A were extracted from the OrthoInspector database version 3.0 (Nevers *et al*, 2019). Using the reference genomes in the OrthoInspector Eukaryotic database, 123 orthologous sequences were identified and a multiple sequence alignment (MSA) was constructed using the Clustal Omega software

(Sievers *et al*, 2011). The MSA was then manually refined to correct local alignment errors using the Jalview MSA editor (Waterhouse *et al*, 2009). The refined MSA was then used as input to the PROBE software (Kress *et al*, 2019), in order to identify conserved regions in the sequences. The sequences in the MSA were divided into five separate clades: Vertebrates, Metazoans, Protists, Plants and Fungi.

In vitro analysis of variant effect on DYRK1A protein

DYRK1A expression plasmids were generated from the pMH-SFB-*DYRK1A* vector containing the human *DYRK1A* cDNA sequence (NM_001396.4) tagged with FLAG peptide at the N-Terminal side (purchased from addgene #101770; Huen lab). Variant sequences were obtained by site-directed mutagenesis with the specific primers and confirmed by Sanger sequencing as described (Quartier *et al*, 2019). HeLa, HEK293 and COS1 cells were maintained and transfected for 24h with *DYRK1A* plasmids (for immunofluorescence) or *DYRK1A* plasmids plus pEGFP-N1 plasmid (for Western Blot) as previously done (Quartier *et al*, 2019). *DYRK1A* proteins were visualized using mouse anti-FLAG antibody (1:1:000; Sigma Aldrich, #F1804), and their level normalized with EGFP (in-house mouse anti-GFP antibody). Immunofluorescence experiments were performed in HeLa cells as previously done (Mattioli *et al*, 2018), and fluorescence was visualized on an inverted confocal microscope (SP2UV, Leica, Wetzlar, Germany). For autophosphorylation analysis, proteins were extracted from HEK293 cells transfected with *DYRK1A* plasmids and immunoprecipitated with anti-FLAG antibody as described (Mattioli *et al*, 2018) with the addition of a phosphatase inhibitor cocktail 2 (Sigma Aldrich). Phosphorylated Tyr321 *DYRK1A* was visualized using rabbit anti-phospho-HIPK2 antibody (1:1000) (Widowati *et al*, 2018) and normalized by the level of total *DYRK1A* protein, visualized using rabbit anti-*DYRK1A* antibody (1:1000; Cohesion Biosciences, #CPA1357). Kinase activity was investigated by co-transfecting *DYRK1A* plasmids and MAPT in HEK293 cells (MAPT_OHu28029C_pcDNA3.1(+)-C-HA from geneScript), adapted from what previously done (Lee *et al*, 2020b). *DYRK1A*, MAPT and pMAPT (Thr212) were visualized using anti-FLAG antibody, anti-TAU-5 antibody (LAS-12808 Thermofisher) and anti-pTAU-T212 antibody (44-740G Thermofisher) and their level normalized with GAPDH (MAB374 Merck). Interaction with DCAF7/WDR68 were visualized using an anti-WDR68 antibody (1:2500; abcam, ab138490). Statistical tests used are indicated in Figures's legends.

287

288 ***DNA methylation signature***

289 Methylation analysis was performed using blood DNA from individuals with *DYRK1A*
 290 LoF (n=16), split into signature discovery (n=10) and validation (n=6) cohorts, based
 291 primarily on whether age at time of blood collection was available, and age- and sex-matched
 292 neurotypical controls (n=24). Whole blood DNA samples were prepared, hybridized to the
 293 Illumina Infinium Human MethylationEPIC BeadChip and analyzed as previously described
 294 (Chater-Diehl *et al*, 2019), a total of n=774,590 probes were analyzed for differential
 295 methylation. Standard quality control metrics showed good data quality for all samples except
 296 Ind#20, which was below the methylated and unmethylated channel median intensity cutoff.
 297 Briefly, *limma* regression with covariates age, sex, and five of the six predicted blood cell
 298 types (i.e. all but neutrophils) identified a DNAm signature with a Benjamini-Hochberg
 299 adjusted *p*-value<0.05 and $|\Delta\beta|>0.10$ (10% methylation difference) comprised of 402 CpG
 300 sites (**Table S3**). Next, we developed a support vector machine (SVM) model with linear
 301 kernel trained on including n=318 non-redundant CpG sites (after CpG sites with >90%
 302 methylation correlation were removed using *caret*) non-redundant CpG sites (Chater-Diehl *et al*, 2019) using the methylation values for the discovery cases vs. controls. The model
 303 generated scores ranging between 0 and 1 (0-100%) for tested samples, classifying samples as
 304 “positive” (score>0.5) or “negative” (score<0.5). Additional neurotypical controls (n=94) and
 305 *DYRK1A* LoF validation samples (n=6) were scored to test model specificity and sensitivity
 306 respectively. EPIC array data from Ind#20 (which failed QC) classified correctly. Also
 307 scored were samples with pathogenic *KMT2A* (n=8) and *ARID1B* (n=4) variants as well as
 308 *DYRK1A* missense (n=10) and distal frameshift (n=1) variants.

310 ***Statistics***

311 All statistic tests were performed using the Prism software. The number of replicates is
 312 mentioned in the method section and in Figure’s legends. The statistical tests used, including
 313 the multiple testing correction methods, are indicated in each figure’s legend.

314

315 **RESULTS**

316 ***Identification of genetic variants in DYRK1A in individuals with ID***

We collected molecular and clinical information from 42 individuals with ID carrying a variant in *DYRK1A* identified in clinical and diagnostic laboratories: structural variants deleting or interrupting *DYRK1A* and recurrent or novel nonsense, frameshift, splice and missense variants (**Table 1, Figure S1**). When blood or fibroblast samples were available, we characterized the consequences of these variants on *DYRK1A* mRNA by RNA-sequencing or RT-qPCR (**Figure S2, Supplementary Text**). For one variant, c.1978del, occurring in the last exon of the gene (**Ind #18**), the mutant transcripts escape to nonsense mRNA mediated decay (NMD) and result in a truncated protein p.Ser660fs (or Ser660Profs*43) retaining its entire kinase domain (**Figure S2F**). The variants occurred *de novo* in most of cases (36/42), one individual had a mosaic father and parental DNA was not available for the others.

Clinical manifestations in individuals with pathogenic variants in DYRK1A and definition of a clinical score

We reviewed the clinical manifestations of the patients with truncating variants, except p.(Ser660fs)(**Supplementary text**). Recurrent features include, consistently with what was previously reported (Bronicki *et al*, 2015; Ji *et al*, 2015; Luco *et al*, 2016; van Bon *et al*, 2016; Earl *et al*, 2017): moderate to severe ID, prenatal or postnatal progressive microcephaly, major speech impairment, feeding difficulties which can be very severe during infancy, seizures and especially history of febrile seizures, autistic traits and anxiety, delayed gross motor development with unstable gait, brain MRI abnormalities including dilated ventricles and corpus callosum hypoplasia and recurrent facial features (**Figure 1A, Supplementary text**). We noted, for the first time, the importance of skin manifestations and especially atopic dermatitis. We also found some genital abnormalities, as already reported (Blackburn *et al*, 2019b) (**Supplementary text**). We used recurrent features to establish a “DYRK1A- clinical score” (CS_{DYRK1A}) on 20 points (**Figure 1A**), which aims to reflect specificity rather than severity of the phenotype. High scores, ranging from 13 to 18.5 (mean=15.5), were obtained for the individuals having a pathogenic variant in *DYRK1A* described here (*DYRK1A_I*) or previously (*DYRK1A_R*) (**Table S1, Figure 1B**). The threshold of CS_{DYRK1A} ≥13 appears to be discriminant between individuals with LoF variants in *DYRK1A* (all ≥13) and individuals suffering from another form of ID (all <13). We then considered CS_{DYRK1A} above 13, comprised between 10 and 13 and below 10 as “highly

suggestive”, “intermediate” and “poorly evokative” respectively. A clinical score without photograph could also be calculated but is less discriminative (**Figure S3**).

In silico analysis of missense variant effects

We evaluated the discriminative power of the CADD score, commonly used in medical genetics (Kircher *et al*, 2014) to interpret missense variants in *DYRK1A*. If a significant difference in the CADD score distribution is observed between the variants presumed to be “benign” (N-set, see **Methods**) and those reported as “pathogenic” by molecular genetic laboratories (P-set, see **Methods**)(p-value<0.0001), a substantial proportion of the N-set variants still have a CADD score above the threshold (20 or 25) usually used to define pathogenicity (**Figure S4A**). This could be explained by the high degree of amino acid conservation of *DYRK1A* among vertebrates, and this could lead to over-interpretation of pathogenicity of missense variants. We performed sequence alignment with more than hundred orthologs of *DYRK1A* from different taxon (**Figure S5**) and confirmed that using sequences from vertebrate species only is not efficient to classify missense variants, as one third of the N-set variants affect amino acids conserved in all the vertebrate species (**Figure S4B**, V=100%). Considering conservation parameters going beyond vertebrates (conserved in 100% of vertebrates, at least 90% of metazoan and at least 80% of other animals) appears more discriminant, keeping most of the variants from P-set (13/16) and only one variant from N-set (**Figure S4B**).

In vitro characterization of consequences of missense variants on DYRK1A protein

In order to test the consequences of the missense variants *in vitro*, we overexpressed wild-type (WT) and mutant *DYRK1A* proteins in three different cell lines (HEK293, HeLa, COS1) and included a truncating variant Arg413fs and a missense variant Ala341Ser from GnomAD as pathogenic and benign variants respectively. A significant decrease in *DYRK1A* protein level, due to a reduction of protein stability (**Figure S6A**), was observed for the truncating variant Arg413fs but also for the missense variants Asp287Val, Ser311Phe, Arg467Gln, Gly168Asp and Ile305Arg (**Figure 2A**). None of the variants affect *DYRK1A* interaction with DCAF7/WDR68 (**Figure S6B**). To be active, *DYRK1A* has to undergo an autophosphorylation on Tyrosine 321 (Himpel *et al*, 2001). To measure the level of active

DYRK1A protein, we detected phospho-DYRK1A (Tyr321) by immunoprecipitation followed by immunoblot using anti-HIPK2, as previously described (Widowati *et al*, 2018)(**Figure 2B**). We observed no difference in the level of phospho-DYRK1A for the Ala341Ser variant compared to the WT protein. We confirmed that the three variants previously tested (Asp287Val, Ser311Phe and Arg467Gln) abolish autophosphorylation (Widowati *et al*, 2018; Arranz *et al*, 2019), as the Gly168Asp and Ile305Arg variants. The Ser324Arg DYRK1A variant showed only residual autophosphorylation. No effect on autophosphorylation was observed for Arg255Gln, Tyr462His, Gly486Asp and Thr588Asn. No effect was detected neither for the Glu366Asp amino acid change, but the analysis of patient's blood mRNA showed that the c.1098G>T variant affect splicing and lead to p.(Ile318_Glu366del) instead of Glu366Asp (**Figure S2G**). We used this strategy to test additional variants reported in databases and showed that Arg158His, affecting a highly conserved amino acid position but reported twice in gnomAD, does not affect DYRK1A protein. Ala277Pro, reported as pathogenic in ClinVar but affecting a position poorly conserved beyond vertebrates, as well as Gly171Arg, Leu241Pro and Pro290Arg, reported as VUS in Clinvar, affect both DYRK1A level and autophosphorylation (**Figure S7A-B, Table S2, Figure S4B**). None of the missense variants appear to affect DYRK1A cellular localization, contrary to Arg413fs variant or mutations NLS domains (**Supplementary Text, Figure S7C**). However, we observed an aggregation of DYRK1A proteins with the distal frameshift variant Ser660fs (**Figure 2C**), which prevents us from correctly measuring the level of mutant protein and its capacity to autophosphorylate.

Identification of a DNAm signature associated with DYRK1A pathogenic variants

To determine if *DYRK1A* is associated with specific changes in genome-wide DNAm in blood, we generated genome-wide methylation profiles using Infinium HumanMethylationEPIC BeadChip arrays. We compared DNAm in blood for a subset (discovery) of our cohort carrying pathogenic LoF variants in *DYRK1A* with age- and sex-matched neurotypical controls and identified n=402 differentially methylated CpG sites (FDR adjusted $p < 0.05$, $|\Delta\beta| > 0.10$), corresponding to 165 RefSeq genes (**Table S3, Figure 3A-B**). We trained a support vector machine (SVM) machine learning model on the DNAm (β) values to generate a score (0-1). We validated its sensitivity and specificity using additional individuals with *DYRK1A* truncating variants (validation), additional controls as well as individuals with pathogenic variants in other epigenetic regulatory genes *ARID1B* and

KMT2A (**Table S4; Figure 3C**). Next, we scored the samples with missense variants in *DYRK1A* and found that six classified positively: samples with p.Asp287Val, p.Ser311Phe, p.Arg467Gln, p.Gly168Asp, p.Ile305Arg and p.Ser324Arg, and three negatively: samples with p.Arg255Gln, p.Tyr462His, p.Thr588Asn (**Figure 3B-C, Table S4, Figure S8**). The sample with the distal frameshift variant p.Ser660fs also classified as DNAm positive, with a relatively high score (0.92). The sample with the p.Gly486Asp variant clustered out from both *DYRK1A* cases and controls using hierarchical clustering and PCA. Specifically, its methylation profile is opposite to *DYRK1A* LoF cases relative to controls, i.e. reduced DNAm at the same sites that demonstrate increased methylation in LoF cases, and increased methylation at sites decreased in LoF cases (**Figure S8**). This pattern is evident when the β values at the top 25 hyper- and hypermethylated signature CpGs are plotted (**Figure S10**). We found that for one third of the signature sites (134/402) the β value for p.Gly486Asp was outside the range observed for that of all discovery controls (**Table S3**), suggesting this variant might have a gain-of-function (GoF) effect. A notable feature of these GoF CpG sites is that they tended to cluster together, as for instance all seven of the signature sites in the *HIST1H3E* promoter (**Table S3**).

Integration of the different tools to reclassify variants

We integrated data from the clinical score (CS_{DYRK1A}), *in silico* predictions, functional assays and DNAm model score to evaluate the pathogenicity of the variants and reclassify them according to ACMG categories (**Figure 4, Table S5**). We found that variants Gly168Asp, Asp287Val, Ile305Arg, Ser311Phe and Arg467Gln, identified in individuals with intermediate to high CS_{DYRK1A} scores, led to reduced protein expression as well as an absence of autophosphorylation activity, which was previously described for three of them (Widowati *et al*, 2018; Arranz *et al*, 2019). All classified as DNAm-positive, definitively supporting their pathogenicity. For the Ser324Arg variant, identified *de novo* in a patient with an intermediate CS_{DYRK1A} score, we observed only a slight decrease of DYRK1A stability and a partial decrease of its autophosphorylation ability. The binary nature of the DNAm signature, showing a positive score, definitively supports its pathogenic effect.

The Arg255Gln and Tyr462His were identified in individuals with very low CS_{DYRK1A} score, they had relatively high CADD score (24 and 29.6) but affect amino acids not highly conserved. They had no effect on protein level, autophosphorylation, and cellular localization

of DYRK1A and classified DNAm-negative. They were therefore both considered to be likely benign. Parental DNA was not available to test the inheritance of Arg255Gln, though it is notable that the variant Tyr462His occurred *de novo*. This individual has an affected brother who does not carry the variant, and exome sequencing of the whole family failed to identify additional promising variants. Another *de novo* variant affecting the same position Tyr462Cys was identified in a girl with mild developmental delay, hypotonia and hypermobility without facial dysmorphism, who finally obtained another molecular diagnosis, i.e. a *de novo* truncating variant in a gene that is currently under investigation as a strong candidate gene for syndromic intellectual disability (personal communication Sander Stegmann, Maastricht University Medical Center). The Thr588Asn variant, previously reported as likely pathogenic (Bronicki *et al*, 2015), appears to have no effect on *DYRK1A* mRNA or on DYRK1A protein level and function, consistent with what was described by others (Widowati *et al*, 2018; Arranz *et al*, 2019). To go further, we tested the ability of the mutant Thr588Asn DYRK1A to phosphorylate MAPT on its Thr212 and confirmed it does not affect its kinase activity (**Figure S9**). Moreover, a knock-in Thr588Asn mouse model was generated and failed to present any decrease of kinase activity and any obvious behavioral phenotype (**Supplementary Text, Figure S11**). The patient's DNAm score was negative, and we therefore reclassified this variant as likely benign. The fact that it occurred *de novo* in a girl with a high CS_{DYRK1A} (15.5/20) remains puzzling, while no additional promising variants were identified in trio-exome sequencing data and no positive classification was found using ~20 DNAm signatures available which could explain this phenocopy.

Only one sample showed a DNAm profile different from controls and individuals with DYRK1A-related ID (**Figure 3A, Figure S8 and S11**). This individual has a very low CS_{DYRK1A}, presenting relative macrocephaly and ASD without ID and carries a *de novo* Gly486Asp variant. This variant was previously reported in another individual with NDD (Dang *et al*, 2018), but it was not possible to obtain DNA or any clinical or inheritance information. No decrease of protein level, autophosphorylation or modification in kinase activity was identified (**Figure S9**), consistent with what was reported by others (Arranz *et al*, 2019). Arranz *et al*. has observed on the contrary an increase of DYRK1A kinase activity, which could suggest a potential GoF effect. However, in their study, they reported a significant increase of kinase activity for five additional variants located all along the protein, including one reported four times in GnomAD (Arg528Trp), which might raise questions

about the sensitivity of the test. We tested the kinase activity of Gly486Asp mutant protein on MAPT Thr212 but could not observed any difference with WT.

We characterized the consequences of a distal frameshift *de novo* variant, Ser660fs. Its overexpression in HeLa cells leads to cytoplasmic aggregation of DYRK1A, which makes difficult to quantify the real effect on protein level, autophosphorylation, or kinase activity on MAPT (**Figure S7 and S10**). However, its DNAm overlaps those of other individuals with truncating variants located further upstream in the protein, confirming its pathogenic effect (**Figure S8**). To test if these aggregations could be driven by the novel C-terminal extension (43 amino acids) added by the frameshift variant, we introduced nonsense variants at the same positions (Ser660* and Ser661*). As no aggregates were detected (**Figure 2C & S8D**), we concluded that the abnormal C-terminal extension of 43 amino acids is responsible for the self-aggregation of the mutant DYRK1A protein. Interestingly, the two truncating variants Ser660* and Ser661* did not affect DYRK1A level, localization or autophosphorylation (**Figure S7A-B**).

DISCUSSION

Here we report clinical manifestations of 32 patients with clear loss-of-function (LoF) variants in *DYRK1A*, refining the clinical spectrum associated with *DYRK1A*-related ID. We used recurrent signs present in more than two-third of the individuals to establish a clinical score, which may seem outdated in the era of pangenomic approaches, but which it is in fact very useful to interpret variants of unknown significance identified by these approaches. Indeed, here we demonstrated that the combination of clinical data together with *in silico* and *in vitro* observations are essential to interpret variants correctly.

Since *DYRK1A* is a highly conserved gene in vertebrates, we assumed that *in silico* prediction tools using conservation calculated mainly from vertebrates might overestimate the potential pathogenicity of missense variants. We showed that deeper conservation analyses using additional taxa are useful to improve the predictions for missense variants. However, *in silico* analyses have their limitations, and functional assays are essential to assess variant effect conclusively. We therefore tested the effect of 17 variants and showed that half of them decreased both DYRK1A protein level and DYRK1A autophosphorylation level. For the remaining variants, no effect on protein function was observed (**Figure 4**). However, the

absence of effects observed during a series of functional tests does not totally exclude a potential effect.

Over the past five years, several studies have found patients with specific monogenic disorders involving genes encoding epigenetic regulatory proteins are associated with DNAm signatures in blood. The advantage of such signatures is a high rate of clear classification (positive vs negative) they provide for variants in most cases as pathogenic or benign. Considering the potential role played by *DYRK1A* in epigenetic regulation (Lepagnol-Bestel *et al*, 2009; Jang *et al*, 2014; Li *et al*, 2018), we wanted to test whether *DYRK1A* LoF leads to such a DNAm signature. We identified a DNAm signature associated with pathogenic variants in *DYRK1A* and demonstrated that it has 100% of sensitivity and specificity (**Figure 3**). The combination of clinical score (CS_{DYRK1A}), *in silico* predictions, functional assays and DNAm signature allow to reclassify ten missense variants as pathogenic while three could be considered as benign: a variant located in the catalytic domain whose inheritance was unknown, Arg255Gln, and two *de novo* variants located at the end or outside of this domain: Tyr462His and Thr588Asn. Though the missense variants classified clearly by the DNAm model, there was a larger range of SVM scores among the positive missense cases than the validation LoF cases (**Figure 3B**). This could indicate a less severe effect of the missense vs. LoF variants, however, there was no correlation between the severity of the variant effect *in vitro* and the SVM score, as illustrated by the high score obtained for the variant Ser324Arg (**Table S4**).

Still based on methylation data, we suspected a gain-of-function (GoF) effect for another *de novo* variant located outside the catalytic domain: Gly486Asp. We have already shown that DNAm profiles at gene-specific signature sites provide a functional readout of each variants effect, GoF activity. Indeed, in previous work, we found the same pattern for a patient with a missense variant in *EZH2*, typically associated with Weaver syndrome. The patient, presenting undergrowth rather than overgrowth characteristic of Weaver syndrome, had an opposite DNAm profile to *EZH2* cases relative to controls and carried a Ala738Thr variant which was demonstrated to increase *EZH2* activity using a luminescence enzymatic assay (Choufani *et al*, 2020). However, we could not confirm the putative GoF effect of Gly486Asp with the kinase assay we performed (phosphorylation of MAPT-Thr212).

We reported here a distal frameshift *de novo* variant occurring in the last exon of *DYRK1A* and escaping to NMD. We showed that the novel C-terminal part of the mutant

protein leads to DYRK1A aggregation *in vitro*, which needs be confirmed *in vivo* in physiological context. Interestingly, the two nonsense changes introduced at this position, Ser660* and Ser661*, did not lead to DYRK1A aggregation, and did not affect neither its expression, ability to autophosphorylate and to phosphorylate MAPT (**Figure 2C, S8C-D, S10**). These results raise questions about the pathogenicity of distal truncating variants which would escape to NMD. Three additional such variants were reported in individuals with ID or NDD in Clinvar and in literature (Okamoto et al., 2015)(**Table S7**). Their clinical interpretation remains ambiguous, especially for c.1726C>T p.Gln576* and c.2040C>A p.Tyr680*, for which inheritance is unknown and clinical manifestations do not really overlap those of *DYRK1A*-related ID. However, the most distal variant ever reported in *DYRK1A*, c.2213_2218delinsAGAG p.Thr738fs, occurred *de novo* in an individual with clinical features consistent with *DYRK1A*-related ID. It would be interesting to obtain DNA and perform DNAm analysis in these three individuals to reclassify these variants.

In conclusion, we developed various tools (clinical score, protein sequence conservation data, *in vitro* functional assays and a specific DNAm signature) to help to better diagnose *DYRK1A*-related ID by improving variant interpretation. This combination of tools was efficient to reclassify variants identified in this gene. We showed that missense variants located outside but also inside the catalytic domain, even occurring *de novo*, as well as variants leading to premature stop codon in the last exon of the gene, are not necessarily pathogenic. These results illustrate that variants in *DYRK1A*, as well as in other NDD causative genes, must be interpreted with caution, even if they occur *de novo*, to avoid over-interpretation. In future, we recommend performing DNAm analysis if blood DNA sample is available or, if not, *in vitro* testing of variant effect on DYRK1A autophosphorylation.

ACKNOWLEDGMENTS

The authors would like to warmly thank the families for their participation to the study, for their trust and their support to our research projects. The authors also thank the Agence de Biomédecine and Fondation APLM for their financial support. We also thank the Centre National de Génotypage (Jean-François Deleuze, Robert Olasso, Anne Boland and the technicians and bioinformaticians) for their participation in library preparation and DNA sequencing. We thank all the people from the GenomEast sequencing platform (Damien Plassard, Céline Keime, Serge Vicaire, Bernard Jost, Stéphanie Le Gras, Mathieu Jung, etc)

for their technical and bioinformatics supports. Also thanks to Paola Rossadillo and Karim Essabri for their help for the cloning and mutagenesis. They thank people for the diagnostic laboratory of Hôpitaux Universitaire de Strasbourg (HUS) for performing follow-up of mutations and giving diagnosis to family (Elsa Nourisson, Céline Cuny, Sylvie Friedman, Carmen Fruchart) and Anais Philippe and Justine Fraize for their help on clinical files.

AUTHOR CONTRIBUTIONS

JC conceived and designed the in vitro experiments, RNA-Seq, RT-PCR experiments ; JC, BDu, IB, LG performed the experiments, performed statistical analysis and analyzed the data related to in vitro experiments ; ND provided technical assistance and performed experiments ; MdM MM, M-C B, YH conceived and created the mouse Thr588Asn knock-in model, designed and performed behavioral experiments ; ES, MN, BG, MA, BC, LB, LB, MB, PC, EC, CC, AD, BD, FD, SP, A-SD, LF, CF, MF, CF, DG, AG, A-MG, BI, KM. J, BK, MK, PK, M MD, BD, JM, RSM, SM, LP, KPS, LPe, MR, PS, JS, JT, FTMT, CET, AV, VL, SD, AB, CD, SEC, CFa, CM, MG, TB, JLM contributed to clinical and molecular data ; AP, BDu, MV, MW compiled the molecular and clinical data and established a clinical score ; Bdu, ES, MZ analyzed and score blindly the facial features ; JT generates multiple sequence alignment and performed conservation analysis; E C-D &, RW conceived, designed and performed the DNA methylation analysis; AP conceived, coordinated, supervised the study; JC & AP wrote the manuscript, with significant contributions of E C-D, RW, BDu, MV, MW & JLM.

CONFLICTS OF INTEREST

None

DATA AVAILABILITY

Variants were submitted to ClinVar database. Additional data are available upon request.

ETHICS DECLARATION

This study was approved by the local Ethics Committee of the Strasbourg University Hospital (Comité Consultatif de Protection des Personnes dans la Recherche Biomédicale (CCPPRB)). All patients enrolled in these genetic studies and/or their legal representative have signed informed consent for genetic testing and authorization for publication.

604

605 WEB RESSOURCES

606 The URLs for online tools and data presented herein are:

607 Clinvar: <http://www.ncbi.nlm.nih.gov/clinvar/>

608 dbSNP : <http://www.ncbi.nlm.nih.gov/projects/SNP/>

609 Decipher: <https://decipher.sanger.ac.uk/>

610 GnomAD: <http://gnomad.broadinstitute.org/>

611 Integrative Genomics Viewer (IGV): <http://www.broadinstitute.org/igv/>

612 Mutation Nomenclature: <http://www.hgvs.org/mutnomen/recs.html>

613 OMIM: <http://www.omim.org/>

614 UCSC: <http://genome.ucsc.edu/>

615 CADD score: <https://cadd.gs.washington.edu/>

616 OrthoInspector database: <https://www.lbgi.fr/orthoinspectordv3/databases>

617

618 BIBLIOGRAPHY

619 Aref-Eshghi E, Bend EG, Colaiacovo S, Caudle M, Chakrabarti R, Napier M, Brick L, Brady L, Carere DA,
620 Levy MA, *et al* (2019) Diagnostic Utility of Genome-wide DNA Methylation Testing in
621 Genetically Unsolved Individuals with Suspected Hereditary Conditions. *Am J Hum Genet* 104:
622 685–700

623 Arranz J, Balducci E, Arató K, Sánchez-Elexpuru G, Najas S, Parras A, Rebollo E, Pijuan I, Erb I, Verde G,
624 *et al* (2019) Impaired development of neocortical circuits contributes to the neurological
625 alterations in DYRK1A haploinsufficiency syndrome. *Neurobiol Dis* 127: 210–222

626 Balak C, Benard M, Schaefer E, Iqbal S, Ramsey K, Ernoult-Lange M, Mattioli F, Llaci L, Geoffroy V,
627 Courel M, *et al* (2019) Rare De Novo Missense Variants in RNA Helicase DDX6 Cause
628 Intellectual Disability and Dysmorphic Features and Lead to P-Body Defects and RNA
629 Dysregulation. *Am J Hum Genet* 105: 509–525

630 Becker W (2011) Recent insights into the function of DYRK1A. *FEBS J* 278: 222

631 Blackburn ATM, Bekheirnia N, Uma VC, Corkins ME, Xu Y, Rosenfeld JA, Bainbridge MN, Yang Y, Liu P,
632 Madan-Khetarpal S, *et al* (2019a) DYRK1A-related intellectual disability: a syndrome

633 associated with congenital anomalies of the kidney and urinary tract. *Genet Med* 21: 2755–
634 2764

635 Blackburn ATM, Bekheirnia N, Uma VC, Corkins ME, Xu Y, Rosenfeld JA, Bainbridge MN, Yang Y, Liu P,
636 Madan-Khetarpal S, *et al* (2019b) DYRK1A-related intellectual disability: a syndrome
637 associated with congenital anomalies of the kidney and urinary tract. *Genet Med* 21: 2755–
638 2764

639 van Bon BWM, Coe BP, Bernier R, Green C, Gerdtts J, Witherspoon K, Kleefstra T, Willemsen MH,
640 Kumar R, Bosco P, *et al* (2016) Disruptive de novo mutations of DYRK1A lead to a syndromic
641 form of autism and ID. *Mol Psychiatry* 21: 126–132

642 van Bon BWM, Hoischen A, Hehir-Kwa J, de Brouwer APM, Ruivenkamp C, Gijsbers ACJ, Marcelis CL,
643 de Leeuw N, Veltman JA, Brunner HG, *et al* (2011) Intragenic deletion in DYRK1A leads to
644 mental retardation and primary microcephaly. *Clin Genet* 79: 296–299

645 Bronicki LM, Redin C, Drunat S, Piton A, Lyons M, Passemard S, Baumann C, Faivre L, Thevenon J,
646 Rivire J-B, *et al* (2015) Ten new cases further delineate the syndromic intellectual disability
647 phenotype caused by mutations in DYRK1A. *Eur J Hum Genet* 23: 1482–1487

648 Butcher DT, Cytrynbaum C, Turinsky AL, Siu MT, Inbar-Feigenberg M, Mendoza-Londono R, Chitayat
649 D, Walker S, Machado J, Caluseriu O, *et al* (2017) CHARGE and Kabuki Syndromes: Gene-
650 Specific DNA Methylation Signatures Identify Epigenetic Mechanisms Linking These Clinically
651 Overlapping Conditions. *Am J Hum Genet* 100: 773–788

652 Carion N, Briand A, Cuisset L, Pacot L, Afenjar A & Bienvenu T (2020) Loss of the KH1 domain of FMR1
653 in humans due to a synonymous variant causes global developmental retardation. *Gene* 753:
654 144793

655 Chater-Diehl E, Ejaz R, Cytrynbaum C, Siu MT, Turinsky A, Choufani S, Goodman SJ, Abdul-Rahman O,
656 Bedford M, Dorrani N, *et al* (2019) New insights into DNA methylation signatures: SMARCA2
657 variants in Nicolaides-Baraitser syndrome. *BMC Med Genomics* 12: 105

658 Choufani S, Cytrynbaum C, Chung BHY, Turinsky AL, Grafodatskaya D, Chen YA, Cohen ASA, Dupuis L,
659 Butcher DT, Siu MT, *et al* (2015) NSD1 mutations generate a genome-wide DNA methylation
660 signature. *Nat Commun* 6: 10207

661 Choufani S, Gibson WT, Turinsky AL, Chung BHY, Wang T, Garg K, Vitriolo A, Cohen ASA, Cyrus S,
662 Goodman S, *et al* (2020) DNA Methylation Signature for EZH2 Functionally Classifies
663 Sequence Variants in Three PRC2 Complex Genes. *Am J Hum Genet* 106: 596–610

664 Courcet J-B, Faivre L, Malzac P, Masurel-Paulet A, Lopez E, Callier P, Lambert L, Lemesle M, Thevenon
665 J, Gigot N, *et al* (2012) The DYRK1A gene is a cause of syndromic intellectual disability with
666 severe microcephaly and epilepsy. *J Med Genet* 49: 731–736

667 Dang T, Duan WY, Yu B, Tong DL, Cheng C, Zhang YF, Wu W, Ye K, Zhang WX, Wu M, *et al* (2018)
668 Autism-associated Dyrk1a truncation mutants impair neuronal dendritic and spine growth
669 and interfere with postnatal cortical development. *Mol Psychiatry* 23: 747–758

670 Deciphering Developmental Disorders Study (2017) Prevalence and architecture of de novo
671 mutations in developmental disorders. *Nature* 542: 433–438

672 Duchon A & Herault Y (2016) DYRK1A, a Dosage-Sensitive Gene Involved in Neurodevelopmental
673 Disorders, Is a Target for Drug Development in Down Syndrome. *Front Behav Neurosci* 10:
674 104

675 Earl RK, Turner TN, Mefford HC, Hudac CM, Gerdtz J, Eichler EE & Bernier RA (2017) Clinical
676 phenotype of ASD-associated DYRK1A haploinsufficiency. *Mol Autism* 8: 54

677 Eng L, Coutinho G, Nahas S, Yeo G, Tanouye R, Babaei M, Dörk T, Burge C & Gatti RA (2004)
678 Nonclassical splicing mutations in the coding and noncoding regions of the ATM Gene:
679 maximum entropy estimates of splice junction strengths. *Hum Mutat* 23: 67–76

680 Ernst J, Alabek ML, Eldib A, Madan-Khetarpal S, Sebastian J, Bhatia A, Liasis A & Nischal KK (2020)
681 Ocular findings of albinism in DYRK1A-related intellectual disability syndrome. *Ophthalmic*
682 *Genet*: 1–6

683 Evers JMG, Laskowski RA, Bertolli M, Clayton-Smith J, Deshpande C, Eason J, Elmslie F, Flinter F,
684 Gardiner C, Hurst JA, *et al* (2017) Structural analysis of pathogenic mutations in the DYRK1A
685 gene in patients with developmental disorders. *Hum Mol Genet* 26: 519–526

686 Fujita H, Torii C, Kosaki R, Yamaguchi S, Kudoh J, Hayashi K, Takahashi T & Kosaki K (2010)
687 Microdeletion of the Down syndrome critical region at 21q22. *Am J Med Genet A* 152A: 950–
688 953

689 Gonzalez-Mantilla AJ, Moreno-De-Luca A, Ledbetter DH & Martin CL (2016) A Cross-Disorder Method
690 to Identify Novel Candidate Genes for Developmental Brain Disorders. *JAMA Psychiatry* 73:
691 275–283

692 Hämmerle B, Elizalde C & Tejedor FJ (2008) The spatio-temporal and subcellular expression of the
693 candidate Down syndrome gene Mnb/Dyrk1A in the developing mouse brain suggests
694 distinct sequential roles in neuronal development. *Eur J Neurosci* 27: 1061–1074

695 Himpe S, Panzer P, Eirnbter K, Czajkowska H, Sayed M, Packman LC, Blundell T, Kentrup H,
696 Grötzinger J, Joost HG, *et al* (2001) Identification of the autophosphorylation sites and
697 characterization of their effects in the protein kinase DYRK1A. *Biochem J* 359: 497–505

698 Iglesias A, Anyane-Yeboah K, Wynn J, Wilson A, Truitt Cho M, Guzman E, Sisson R, Egan C & Chung WK
699 (2014) The usefulness of whole-exome sequencing in routine clinical practice. *Genet Med* 16:
700 922–931

701 Jang SM, Azebi S, Soubigou G & Muchardt C (2014) DYRK1A phosphorylates histone H3 to differentially
702 regulate the binding of HP1 isoforms and antagonize HP1-mediated transcriptional
703 repression. *EMBO Rep* 15: 686–694

704 Ji J, Lee H, Argiropoulos B, Dorrani N, Mann J, Martinez-Agosto JA, Gomez-Ospina N, Gallant N,
705 Bernstein JA, Hudgins L, *et al* (2015) DYRK1A haploinsufficiency causes a new recognizable
706 syndrome with microcephaly, intellectual disability, speech impairment, and distinct facies.
707 *Eur J Hum Genet* 23: 1473–1481

708 Kim O-H, Cho H-J, Han E, Hong TI, Ariyasiri K, Choi J-H, Hwang K-S, Jeong Y-M, Yang S-Y, Yu K, *et al*
709 (2017) Zebrafish knockout of Down syndrome gene, DYRK1A, shows social impairments
710 relevant to autism. *Mol Autism* 8: 50

711 Kircher M, Witten DM, Jain P, O’Roak BJ, Cooper GM & Shendure J (2014) A general framework for
712 estimating the relative pathogenicity of human genetic variants. *Nat Genet* 46: 310–315

713 Lee K-S, Choi M, Kwon D-W, Kim D, Choi J-M, Kim A-K, Ham Y, Han S-B, Cho S & Cheon CK (2020a) A
714 novel de novo heterozygous DYRK1A mutation causes complete loss of DYRK1A function and
715 developmental delay. *Sci Rep* 10: 9849

716 Lee K-S, Choi M, Kwon D-W, Kim D, Choi J-M, Kim A-K, Ham Y, Han S-B, Cho S & Cheon CK (2020b) A
717 novel de novo heterozygous DYRK1A mutation causes complete loss of DYRK1A function and
718 developmental delay. *Sci Rep* 10: 9849

719 Lepagnol-Bestel A-M, Zvara A, Maussion G, Quignon F, Ngimbous B, Ramoz N, Imbeaud S, Loe-Mie Y,
720 Benihoud K, Agier N, *et al* (2009) DYRK1A interacts with the REST/NRSF-SWI/SNF chromatin
721 remodelling complex to deregulate gene clusters involved in the neuronal phenotypic traits
722 of Down syndrome. *Hum Mol Genet* 18: 1405–1414

723 Li S, Xu C, Fu Y, Lei P-J, Yao Y, Yang W, Zhang Y, Washburn MP, Florens L, Jaiswal M, *et al* (2018)
724 DYRK1A interacts with histone acetyl transferase p300 and CBP and localizes to enhancers.
725 *Nucleic Acids Res* 46: 11202–11213

726 Luco SM, Pohl D, Sell E, Wagner JD, Dymont DA & Daoud H (2016) Case report of novel DYRK1A
727 mutations in 2 individuals with syndromic intellectual disability and a review of the literature.
728 *BMC Med Genet* 17: 15

729 Mary L, Piton A, Schaefer E, Mattioli F, Nourisson E, Feger C, Redin C, Barth M, El Chehadeh S, Colin E,
730 *et al* (2018) Disease-causing variants in TCF4 are a frequent cause of intellectual disability:
731 lessons from large-scale sequencing approaches in diagnosis. *Eur J Hum Genet* 26: 996–1006

732 Matsumoto N, Ohashi H, Tsukahara M, Kim KC, Soeda E & Niihara N (1997) Possible narrowed
733 assignment of the loci of monosomy 21-associated microcephaly and intrauterine growth
734 retardation to a 1.2-Mb segment at 21q22.2. *Am J Hum Genet* 60: 997–999

735 Meissner LE, Macnamara EF, D’Souza P, Yang J, Vezina G, Undiagnosed Diseases Network, Ferreira
736 CR, Zein WM, Tiffet CJ & Adams DR (2020) DYRK1A pathogenic variants in two patients with
737 syndromic intellectual disability and a review of the literature. *Mol Genet Genomic Med*:
738 e1544

739 Møller RS, Kübart S, Hoeltzenbein M, Heye B, Vogel I, Hansen CP, Menzel C, Ullmann R, Tommerup N,
740 Ropers H-H, *et al* (2008) Truncation of the Down syndrome candidate gene DYRK1A in two
741 unrelated patients with microcephaly. *Am J Hum Genet* 82: 1165–1170

742 Murray CR, Abel SN, McClure MB, Foster J, Walke MI, Jayakar P, Bademci G & Tekin M (2017) Novel
743 Causative Variants in DYRK1A, KARS, and KAT6A Associated with Intellectual Disability and
744 Additional Phenotypic Features. *J Pediatr Genet* 6: 77–83

745 Nasser H, Vera L, Elmaleh-Bergès M, Steindl K, Letard P, Teissier N, Ernault A, Guimiot F, Afenjar A,
746 Moutard ML, *et al* (2020) CDK5RAP2 primary microcephaly is associated with hypothalamic,
747 retinal and cochlear developmental defects. *J Med Genet* 57: 389–399

748 Nevers Y, Kress A, Defosset A, Ripp R, Linard B, Thompson JD, Poch O & Lecompte O (2019)
749 OrthoInspector 3.0: open portal for comparative genomics. *Nucleic Acids Res* 47: D411–D418

750 Oegema R, de Klein A, Verkerk AJ, Schot R, Dumee B, Douben H, Eussen B, Dubbel L, Poddighe PJ, van
751 der Laar I, *et al* (2010) Distinctive Phenotypic Abnormalities Associated with Submicroscopic
752 21q22 Deletion Including DYRK1A. *Mol Syndromol* 1: 113–120

753 Okamoto N, Miya F, Tsunoda T, Kato M, Saitoh S, Yamasaki M, Shimizu A, Torii C, Kanemura Y &
754 Kosaki K (2015) Targeted next-generation sequencing in the diagnosis of
755 neurodevelopmental disorders. *Clin Genet* 88: 288–292

756 O’Roak BJ, Vives L, Fu W, Egertson JD, Stanaway IB, Phelps IG, Carvill G, Kumar A, Lee C, Ankenman K,
757 *et al* (2012) Multiplex targeted sequencing identifies recurrently mutated genes in autism
758 spectrum disorders. *Science* 338: 1619–1622

759 Qiao F, Shao B, Wang C, Wang Y, Zhou R, Liu G, Meng L, Hu P & Xu Z (2019) A De Novo Mutation in
760 DYRK1A Causes Syndromic Intellectual Disability: A Chinese Case Report. *Front Genet* 10:
761 1194

762 Quartier A, Chatrousse L, Redin C, Keime C, Haumesser N, Maglott-Roth A, Brino L, Le Gras S,
763 Benchoua A, Mandel J-L, *et al* (2018) Genes and Pathways Regulated by Androgens in Human
764 Neural Cells, Potential Candidates for the Male Excess in Autism Spectrum Disorder. *Biol*
765 *Psychiatry*

766 Quartier A, Courraud J, Thi Ha T, McGillivray G, Isidor B, Rose K, Drouot N, Savidan M-A, Feger C,
767 Jagline H, *et al* (2019) Novel mutations in NLGN3 causing autism spectrum disorder and
768 cognitive impairment. *Hum Mutat* 40: 2021–2032

769 Redin C, Gérard B, Lauer J, Herenger Y, Muller J, Quartier A, Masurel-Paulet A, Willems M, Lesca G, El-
770 Chehadeh S, *et al* (2014) Efficient strategy for the molecular diagnosis of intellectual disability
771 using targeted high-throughput sequencing. *J Med Genet* 51: 724–736

772 Reese MG, Eeckman FH, Kulp D & Haussler D (1997) Improved splice site detection in Genie. *J*
773 *Comput Biol* 4: 311–323

774 Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E, *et al*
775 (2015) Standards and guidelines for the interpretation of sequence variants: a joint
776 consensus recommendation of the American College of Medical Genetics and Genomics and
777 the Association for Molecular Pathology. *Genet Med* 17: 405–424

778 Ruaud L, Mignot C, Guët A, Ohl C, Nava C, Héron D, Keren B, Depienne C, Benoit V, Maystadt I, *et al*
779 (2015) DYRK1A mutations in two unrelated patients. *Eur J Med Genet* 58: 168–174

780 Rump P, Jazayeri O, van Dijk-Bos KK, Johansson LF, van Essen AJ, Verheij JBGM, Veenstra-Knol HE,
781 Redeker EJW, Mannens MMAM, Swertz MA, *et al* (2016) Whole-exome sequencing is a
782 powerful approach for establishing the etiological diagnosis in patients with intellectual
783 disability and microcephaly. *BMC Med Genomics* 9: 7

784 Sievers F, Wilm A, Dineen D, Gibson TJ, Karplus K, Li W, Lopez R, McWilliam H, Remmert M, Söding J,
785 *et al* (2011) Fast, scalable generation of high-quality protein multiple sequence alignments
786 using Clustal Omega. *Mol Syst Biol* 7: 539

787 Tejedor FJ & Hämmerle B (2011) MNB/DYRK1A as a multiple regulator of neuronal development.
788 *FEBS J* 278: 223–235

- 789 Tran KT, Le VS, Bui HTP, Do DH, Ly HTT, Nguyen HT, Dao LTM, Nguyen TH, Vu DM, Ha LT, *et al* (2020)
790 Genetic landscape of autism spectrum disorder in Vietnamese children. *Sci Rep* 10: 5034
- 791 Valetto A, Orsini A, Bertini V, Toschi B, Bonuccelli A, Simi F, Sammartino I, Taddeucci G, Simi P &
792 Saggese G (2012) Molecular cytogenetic characterization of an interstitial deletion of
793 chromosome 21 (21q22.13q22.3) in a patient with dysmorphic features, intellectual disability
794 and severe generalized epilepsy. *Eur J Med Genet* 55: 362–366
- 795 Vissers LELM, Gilissen C & Veltman JA (2016) Genetic studies in intellectual disability and related
796 disorders. *Nat Rev Genet* 17: 9–18
- 797 Waterhouse AM, Procter JB, Martin DMA, Clamp M & Barton GJ (2009) Jalview Version 2--a multiple
798 sequence alignment editor and analysis workbench. *Bioinformatics* 25: 1189–1191
- 799 Widowati EW, Ernst S, Hausmann R, Müller-Newen G & Becker W (2018) Functional characterization
800 of DYRK1A missense variants associated with a syndromic form of intellectual deficiency and
801 autism. *Biol Open* 7
- 802 Woods YL, Cohen P, Becker W, Jakes R, Goedert M, Wang X & Proud CG (2001) The kinase DYRK
803 phosphorylates protein-synthesis initiation factor eIF2Bepsilon at Ser539 and the
804 microtubule-associated protein tau at Thr212: potential role for DYRK as a glycogen synthase
805 kinase 3-priming kinase. *Biochem J* 355: 609–615
- 806 Yamamoto T, Shimojima K, Nishizawa T, Matsuo M, Ito M & Imai K (2011) Clinical manifestations of
807 the deletion of Down syndrome critical region including DYRK1A and KCNJ6. *Am J Med Genet*
808 A 155A: 113–119

809

810

811

812

813

814

815

816 **FIGURE LEGENDS**

817 **Figure 1. Clinical score for Intellectual Disability associated to *DYRK1A***
818 **haploinsufficiency**

819 **(A)** Clinical score out of 20 points established according to the most recurrent clinical features
820 presented by patients (the weight assigned to each symptom being based on its recurrence):

clinical symptoms are out of 15 points, while the facial appearance is out of 5 points. EV: enlarged ventricles; CCA/H: corpus callosum agenesis or hypoplasia, CA: cerebral atrophy, CeA: cerebellar atrophy (B) Clinical scores calculated for individuals carrying pathogenic variants in *DYRK1A* reported here and for whom photographs were available (n=21)(initial cohort, *DYRK1A_I*, scores 13- 17.5 with a mean of 15.5), the previously published individuals (replication cohort, *DYRK1A_R*, scores 13.5-18, mean=15.3) and the individuals affected with other frequent monogenic forms of ID, associated to mutations in *ANKRD11*, *MED13L*, *DDX3X*, *ARID1B*, *SHANK3*, *TCF4* or *KMT2A* (scores 3-12.5, mean=7). The clinical score for the individuals carrying missense or distal frameshift variants are indicated in yellow (test); The threshold of $CS_{DYRK1A} \geq 13$ appeared to be discriminant between individuals with LoF variants in *DYRK1A* (all ≥ 13) and individuals suffering from another form of ID (all < 13) and a score above this threshold was therefore considered “highly suggestive”. We classified individuals with $CS_{DYRK1A} < 10$ as “poorly evokative” and individuals with a CS_{DYRK1A} comprised between 10 and 13 as “intermediate”. Brown-Forsythe and Welsh ANOVA tests with Dunnett’s T 3 multiple comparisons test were performed. ns: not significant; ** $p < 0.01$; *** $p < 0.001$, error bars represent SD.

Figure 2. Expression, localization and Tyr321 phosphorylation of *DYRK1A* mutant proteins

(A) Level of variant *DYRK1A* proteins expressed in HeLa, HEK293 and COS cells transiently transfected with *DYRK1A* constructs. Protein levels were normalized on the level of GFP proteins (expressed from a cotransfected pEGFP plasmid). Quantifications were performed on a total of n ≥ 9 series of cells (n ≥ 3 HeLa cells, n ≥ 3 HEK293 and n ≥ 3 COS cells). One-way ANOVA with multiple comparison test was performed to compare the level of variant *DYRK1A* proteins to the level of wild-type *DYRK1A* protein, applying Bonferroni’s correction: ns: not significant; * $p < 0.05$; ** $p < 0.01$; *** $p < 0.001$; error bars represent SEM, standard error of the mean, (B) *DYRK1A*’s ability to autophosphorylate on Tyr321 was tested in HEK293 cells (n=3) by immunoprecipitations with anti-*DYRK1A* followed by an immunoblot using an anti-HIPK2 as described in Widowati et al. *DYRK1A* phospho-Tyr321 levels were normalized with *DYRK1A* total level. Variant *DYRK1A* phospho-Tyr321 levels were normalized with total *DYRK1A* protein levels and expressed as percentage of wild-type level. One-way ANOVA test was performed to compare variants to wild-type *DYRK1A* levels. ns: not significant; *** $p < 0.001$; error bars represent SEM, standard error of the mean (C) Immunofluorescence experiment showing that Ser660fs (alias

Ser660Profs*43) variant leads to DYRK1A protein aggregation when overexpressed in HeLa cells, using a FLAG-tagged DYRK1A proteins carrying Ser660Profs43. No aggregation was observed for the Ser660* variant.

Figure 3. DNA methylation signature of DYRK1A loss-of-function functionally classifies DYRK1A VUS.

(A) Heatmap showing the hierarchical clustering of discovery *DYRK1A* LoF cases (n=10) and age- and sex-matched neurotypical discovery controls (n=24) used to identify the 402 differentially methylated signature sites shown. The color gradient represents the normalized DNA methylation value from -2.0 (blue) to 2.0 (yellow) at each site. DNA methylation at these sites clearly separate discovery cases (grey) from discovery controls (blue). Euclidian distance metric is used for the clustering dendrogram. (B) Principal components analysis (PCA) visualizing the DNAm profiles of the study cohort at the 402 signature sites. Validation of *DYRK1A* LoF cases (not used to define the signature sites; red) cluster with discovery cases, while missense (yellow) and distal LoF (green) variants cluster with either cases or controls. Ind #33 (Gly486Asp) has an opposite DNAm profile to *DYRK1A* LoF cases at these sites, suggesting a GoF. (C) Support vector machine (SVM) classification model based on the DNA methylation values in the discovery groups. Each sample is plotted based on its scoring by the model. All samples are clearly positive (>0.5) or negative (<0.5). All *DYRK1A* validation cases from our cohort (n=6) classified positively, all control validation cases (n=94) classified negatively. Missense variants classified clearly positively or negatively, the distal frameshift variant (Ind #18, c.1978del), analyzed in duplicate, classified positively. Pathogenic *ARID1B* (Coffin-Siris syndrome) and *KMT2A* (Wiedemann Steiner syndrome) also classified negatively.

Figure 4. Summary of the analysis performed to reclassify variants in DYRK1A

Representation of the DYRK1A protein (the kinase domain is indicated in red and the catalytic domain in dark red) with the positions of the different variants tested with the sample #ID of the individuals indicated inside the circles. Number: number of individuals with ID reported with the variant; gAD: variant reported in individuals from gnomAD; CS_{DYRK1A} poorly (white), intermediate (grey) or highly (black) evocative, or unknown (-); CADD below

25 (white), between 25 and 30 (grey) or above 30 (black); conservation: highly conserved V=100%, M>90%, O>80% (black), moderately V=100%, M>90%, O<80% (grey) or midly V=100% M<90%, O<80% (white); Expression or autophosphorylation being normal (white), intermediate decreased (grey), strongly decreased (black); Localization was normal (white), affected (grey) or not tested (-); DNAmethylation positive (black), negative (white), suggestive of a GoF effect (hashed) or not tested (-). Final classification: Pathogenic (P), Benign (B), Unknown significance (U).

Table 1. List of variants identified in *DYRK1A* in individuals with intellectual disability

del: deletion of the gene ; Trans.: translocation interrupting the gene ; Ns: nonsense ; Fs: frameshift, Spl: splice ; Ms: missense variants; TES: targeted exome sequencing of ID genes TES¹ : panel of ID genes from Carion et al. ⁴⁷; TES² : panel of ID gene adapted from Redin et al. ⁴⁶; TES³ : panel of 44 ID genes; TES⁴: panel of microcephaly genes from Nasser et al. ⁴⁸ ; CES: clinical exome sequencing, ES: exome sequencing, Sanger: Sanger sequencing, CGH-array: comparative genomic hybridization-array. ^a: the consequences of c.1098G>T is p.Ile318_Glu366del instead of p.Glu366Asp ; M : male ; F : female ; DYRK1A_I : initial cohort used to establish DYRK1A clinical score (CS_{DYRK1A}) ; DYRK1A_R : replication cohort used to confirm the relevance of the CS_{DYRK1A} ; Disc : discovery cohort used to establish DNA methylation signature (DNAm) ; Valid: validation cohort used to confirm DNA methylation signature (DNAm); test : variants tested for pathogenicity using DNAm.

Variant					Individual			Reporting		Analyses performed				
GRCh37 (Chr21)	NM_001396.4	NP_001387.2	Type	Method	Ind	Sex	Inherit.	This individual (ClinVar)	Additional ind. (ClinVar)	CS _{DYRK1A}	<i>In silico</i>	mRNA	<i>in vitro</i>	DNAm
g:38481804_40190458del (<i>DYRK1A</i> ; >10 other genes)	NA	NA	del.	CGH-array	Ind #1	M	de novo	this report	NA	DYRK1A_↓	-	yes	-	Disc.
g:38722881_39426450del (<i>DYRK1A</i> ; <i>KCNJ2</i>)	NA	NA	del.	CGH-array	Ind #2	F	de novo	this report	NA	DYRK1A_↓	-	-	-	-
g:38302140_40041414del (<i>DYRK1A</i> ; >5 other genes)	NA	NA	del.	CGH-array	Ind #40	M	de novo	this report	NA	DYRK1A_↓	-	-	-	-
t(9;21)(p12;q22)	Between exon 2 & 3	NA	transl.	CGH-array	Ind #3	M	de novo	this report	NA	DYRK1A_↓	-	-	-	-
g:38852961C>T	c.349C>T	p.Arg117*	Ns	ES	Ind #4	M	NA	this report	(5x) VCV000373087	DYRK1A_↓	-	-	-	-
				ES	Ind #5	F	father mosaic	this report		DYRK1A_↓	-	-	-	-
				ES	Ind #6	M	de novo	this report		DYRK1A_↓	-	-	-	Disc.
g:38862575C>T	c.763C>T	p.Arg255*	Ns	TES ¹	Ind #7	M	de novo	this report	(5x) VCV000162152	DYRK1A_↓	-	-	-	Valid.
g:38862611C>T	c.799C>T	p.Gln267*	Ns	ES	Ind #35	M	de novo	this report	-	DYRK1A_↓	-	-	-	-
g:38862748T>A	c.936T>A	p.Cys312*	Ns	CES	Ind #37	F	de novo	this report	-	DYRK1A_↓	-	-	-	-
g:38877655C>T	c.1309C>T	p.Arg437*	Ns	TES ⁴	Ind #34	F	NA	this report	(7x) VCV000162158	DYRK1A_↓	-	-	-	-
g:38877745C>T	c.1399C>T	p.Arg467*	Ns	TES ⁴	Ind #42	F	de novo	this report	(3x) VCV000204005	DYRK1A_↓	-	-	-	-
g:38850510dup	c.235dup	p.Arg79fs	Fs	TES ⁴	Ind #41	F	de novo	this report (=SCV001432470)	-	DYRK1A_↓	-	-	-	-
g:38850565_38850566del	c.290_291 del	p.Ser97fs	Fs	CES	Ind #8	M	de novo	this report	(2x) VCV000418949	DYRK1A_↓	-	-	-	-
g:38850572_38850576del	c.297_301del	p.Leu100fs	Fs	NA	Ind #9	M	de novo	this report (=SCV000485020)	-	DYRK1A_↓	-	-	-	-
g:38853089del	c.477del	p.Tyr159*	Fs	ES	Ind #10	F	de novo	this report	-	DYRK1A_↓	-	-	-	-
g:38862514_38862515del	c.702_703del	p.Cys235fs	Fs	ES	Ind #11	M	de novo	this report	-	DYRK1A_↓	-	yes	-	Valid.
g:38862594del	c.782del	p.Leu261fs	Fs	TES ²	Ind #12	F	de novo	this report	-	DYRK1A_↓	-	-	-	Disc.
g:38865371del	c.1004del	p.Gly335fs	Fs	TES ¹	Ind #13	F	absent in mother	this report	-	DYRK1A_↓	-	-	-	Valid.
g:38865375dup	c.1008dup	p.Pro337fs	Fs	ES	Ind #14	F	de novo	this report	-	DYRK1A_↓	-	-	-	-
g:38865400del	c.1033del	p.Trp345fs	Fs	CES	Ind #15	F	de novo	this report	-	DYRK1A_↓	-	-	-	Disc.
g:38877616del	c.1270del	p.His424fs	Fs	ES	Ind #39	F	de novo	this report	-	DYRK1A_↓	-	-	-	-
g:38877679dup	c.1333dup	p.Thr445fs	Fs	ES	Ind #16	F	de novo	this report (=SCV000778256.1)	-	DYRK1A_↓	-	-	-	Disc.
g:38877837del	c.1491delC	p.Ala498fs	Fs	ES	Ind #17	F	de novo	this report	-	DYRK1A_↓	-	-	-	Valid.
g:38884520del	c.1978del	p.Ser660fs= p.Ser660Profs*43	Fs	TES ¹	Ind #18	F	de novo	this report	-	test	-	yes	yes	test
g:38852939G>T	c.328-1G>T	p.?	Spl.	TES ²	Ind #19	F	de novo	this report	-	DYRK1A_↓	-	yes	-	Disc.
g:38862475A>G	c.665-2A>G	p.?	Spl.	Sanger	Ind #20	M	de novo	this report	SCV000492145	DYRK1A_↓	-	-	-	Valid.
g:38862468_38862472del	c.665-9_665-5del	p.?	Spl.	Sanger	Ind #21	M	de novo	this report	SCV000677027	DYRK1A_↓	-	-	-	Disc.
			Spl.	TES ²	Ind #36	M	de novo	this report		DYRK1A_↓	-	-	-	-

g.38862764G>C	951+1G>C	p.?	Spl.	TES ¹	Ind #38	M	de novo	this report	-	DYRK1A_I	-	-	-	Valid.
g.38862767_38862770del	c.951+4_951+7del	p.?	Spl.	ES	Ind #22	M	de novo	this report (=SCV000435011.5)	SCV000709803	DYRK1A_I	-	yes	-	-
g.38877584A>G	c.1240-2A>G	p.?	Spl.	ES	Ind #23	M	de novo	this report (=SCV000966166)	-	DYRK1A_I	-	-	-	Disc.
g.38877585_38877586insTAA	c.1240-1_1240insTAA	p.?	Spl.	TES ⁴	Ind #24	F	de novo	this report	-	DYRK1A_I	-	yes	-	-
g.38853115G>A	c.503G>A	p.Gly168A ^{sp}	Mis.	TES ¹	Ind #25	F	de novo	this report	SCV000573105	test	yes	-	yes	test
g.38862576G>A	c.764G>A	p.Arg255Gln	Mis.	TES ¹	Ind #26	F	NA	this report	-	test	yes	-	yes	test
g.38862672A>T	c.860A>T	p.Asp287Val	Mis.	ES	Ind #27	M	de novo	this report (=SCV000598121)	SCV001446739	test	yes	-	yes	test
g.38862726T>G	c.914T>G	p.Ile305Arg	Mis.	Sanger	Ind #28	F	de novo	this report	-	test	yes	-	yes	test
g.38865339T>A	c.972T>A	p.Ser324Arg	Mis.	TES ³	Ind #29	M	de novo	this report (=SCV000902439)	-	test	yes	-	yes	test
g.38865465G>T	c.1098G>T ³	p.Glu366A ^{sp}	Mis.	ES	Ind #30	F	de novo	this report	-	test	yes	yes	yes	-
g.38877730T>C	c.1384T>C	p.Tyr462His	Mis.	TES ²	Ind #31	M	de novo	this report (=SCV001437769)	-	test	yes	-	yes	test
g.38877746G>A	c.1400G>A	p.Arg467Gln	Mis.	TES ²	Ind #32	F	de novo	this report (=SCV001437771)	(3x) VVCV000209150	test	yes	-	yes	test
g.38877803G>A	c.1457G>A	p.Gly486A ^{sp}	Mis.	ES	Ind #33	M	de novo	this report (SCV000747759)	-	test	yes	-	yes	test

Variants previously reported :

g.38858865C>T	c.613C>T	p.Arg205*	NS	TES ²	Bronicki_#2	M	de novo	PMID: 25920557 (SCV000281731=SCV000196058)	(x7) VVCV000162153	DYRK1A_R	-	-	-	-
g.38862656dup	c.844dup	p.Ser282fs	FS	TES ¹	Bronicki_#8	M	De novo	PMID: 25920557 (SCV000196064)	-	DYRK1A_R	-	-	-	-
g.38858873_38858876delinsGAA	c.621_624 delinsGAA	p.Glu208fs	FS	TES ²	Bronicki_#3	M	de novo	PMID: 25920557 (SCV000281736 = SCV000196059.1)	-	DYRK1A_R	-	-	-	Disc.
g.38868553dup	c.1232dup	p.Arg413fs	FS	TES ²	Bronicki_#10	F	de novo	PMID: 25920557 (SCV000196066)	-	DYRK1A_R	-	yes	yes	Disc.
g.38862744C>T	c.932C>T	p.Ser311Phe	Mis	NA	Ruud_#2	M	de novo	PMID: 25641759 (SCV000586742)	SCV000520979	test	yes	-	yes	test
g.38884305C>A	c.1763C>A	p.Thr588Asn	Mis	ES	Bronicki_#9	F	de novo	PMID: 25920557 (SCV000965705.1=SCV000196065.1)	-	test	yes	yes	yes	test

Table 1. List of variants identified in *DYRK1A* in individuals with intellectual disability

A

Frequent features (% ind. this report - prev. reported)	Points (/20)
Intellectual disability (100% - 100%) (<i>moderate:1; severe:2</i>)	2
Impaired language (100% - 100%) (<i>yes:1; absence or few words:2</i>)	2
Microcephaly (100% - 94%) (<i>yes:1; severe <-3SD:2</i>)	2
Feeding difficulty (neonate or infancy)(93% - 88%)	2
History of seizures (90% - 74%) (<i>yes:1; febrile seizures :2</i>)	2
Autistic traits/Anxiety (93% - 89%) (<i>Anxiety:1; Stereotypies:1; ASD diagnosis:2</i>)	2
Brain anomaly on MRI (83% - 75%) (<i>any:0,5; if EV, CCA/H, CA, CeA:1</i>)	1
Motor delay (83% - 88%)	1
Ataxic walk/hypertonia (62% - 73%)	0.5
Atopic or translucide skin (69% -)	0.5
Dysmorphism:	
<i>Thin hair or erratic hairline</i>	0.5
<i>Upper eyelid edema</i>	1
<i>Deep set eyes</i>	1
<i>Protruding nose or pointed nasal tip</i>	0.5
<i>Dysplastic ears or ear lobe attached</i>	0.5
<i>Thin upper lip</i>	0.5
<i>Widely spaced teeth, protruding upper dental arch</i>	0.5
<i>Retrognathism, smal chin</i>	0.5

B

Figure 1